trending Market Intelligence /marketintelligence/en/news-insights/trending/Jesx5sN-XrRRDs_5xyKVaw2 content esgSubNav
In This List

Neurotrope adds 2 directors

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Neurotrope adds 2 directors

Neurotrope Inc. appointed Ivan Gergel and Jonathan Schechter to its board.

Gergel is the managing partner and chief medical officer of New Rhein Healthcare Investors LLC, while Schechter is director of investment banking at Chardan Capital Markets.

Neurotrope is a biopharmaceutical company focused on developing a product platform for the treatment of Alzheimer's disease.